X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.fiercepharma.com/pharma/amgen-stumbled-bristol-myers-touts-kras-confirmatory-trial-win-newly-bought-krazati
https://endpts.com/fda-declines-to-grant-amgens-lumakras-full-approval-in-lung-cancer-after-negative-advisory-committee-vote/
https://www.fiercepharma.com/fierce-biotech/esmo-amgen-sticks-lumakras-high-dose-touts-new-colorectal-cancer-data
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-panel-gives-thumbs-down-approval-amgen-lung-cancer-drug-2023-10-05/
https://www.reuters.com/business/healthcare-pharmaceuticals/fda-staff-says-late-stage-data-not-enough-amgens-lung-cancer-drug-2023-10-03/
https://www.fiercepharma.com/pharma/fda-document-waves-red-flags-over-systemic-bias-amgens-lumakras-study-ahead-advisory
https://www.prnewswire.com/news-releases/amgen-presents-new-lumakras-sotorasib-plus-chemotherapy-data-in-first-line-kras-g12c-nsclc-at-wclc-301922393.html
https://www.onclive.com/view/bazhenova-details-potential-pathways-forward-for-targeting-kras-mutations-in-nsclc
https://www.globenewswire.com/news-release/2022/12/07/2569720/0/en/Revolution-Medicines-to-Regain-Global-Rights-to-RMC-4630-following-Sanofi-s-Termination-of-SHP2-Inhibitor-Development-and-Commercialization-Collaboration.html
https://endpts.com/philip-tagari-switches-amgens-discovery-lab-for-insitros-machine-learning-tools-ceo-joaquin-duato-to-chair-jjs-board/
https://www.globenewswire.com/news-release/2022/10/11/2531696/0/en/BridgeBio-Pharma-Announces-First-Lung-Cancer-Patient-Dosed-in-Phase-1-2-Trial-and-US-FDA-Fast-Track-Designation-for-SHP2-inhibitor-BBP-398-in-Combination-with-Amgen-s-LUMAKRAS-soto.html
https://www.prnewswire.com/news-releases/lumakras-sotorasib-combined-with-vectibix-panitumumab-shows-confirmed-30-objective-response-rate-in-patients-with-kras-g12c-mutated-metastatic-colorectal-cancer-301621681.html
https://www.prnewswire.com/news-releases/lumakraslumykras-sotorasib-demonstrates-superior-progression-free-survival-over-docetaxel-in-first-positive-phase-3-trial-of-a-kras-g12c-inhibitor-in-non-small-cell-lung-cancer-301621632.html
https://www.prnewswire.com/news-releases/amgen-announces-topline-data-from-lumakras-sotorasib-phase-3-trial-in-non-small-cell-lung-cancer-301615013.html
https://www.fiercepharma.com/pharma/lumakras-first-keytruda-combo-data-flag-safety-concern-amgen-presses-ahead
https://www.fiercepharma.com/marketing/amgen-outlines-lumakras-newly-diagnosed-lung-cancer-plan-kras-launch-hits-snag
https://endpts.com/amgens-blockbuster-hopeful-lumakras-sees-slower-than-expected-sales-in-latest-data-analyst-says/
https://www.fiercebiotech.com/biotech/its-all-tied-adagrasib-and-lumakras-identical-researcher-says
https://www.prnewswire.com/news-releases/lumakras-sotorasib-codebreak-100-study-shows-two-year-overall-survival-of-32-5-in-patients-with-kras-g12c-mutated-advanced-non-small-cell-lung-cancer-301520510.html
https://www.fiercepharma.com/pharma/amgen-s-lumakras-produces-encouraging-results-pancreatic-cancer-though-not-as-dazzling-as
https://www.prnewswire.com/news-releases/lumakras-sotorasib-shows-encouraging-and-clinically-meaningful-anticancer-activity-in-patients-with-kras-g12c-mutated-advanced-pancreatic-cancer-in-codebreak-100-trial-301481914.html
https://www.prnewswire.com/news-releases/lumakras-sotorasib-receives-approval-in-japan-for-patients-with-kras-g12c-mutated-advanced-non-small-cell-lung-cancer-301464697.html
https://www.pharmatimes.com/news/amgen_reveals_new_combination_data_for_kras_inhibitor_1380387
https://www.fiercebiotech.com/biotech/mirati-sanofi-join-forces-lung-cancer-a-kras-shp2-combo-approach
https://www.fiercepharma.com/pharma/amgen-s-latest-lumakras-data-kras-cancer-underscore-bumpy-road-for-combo-strategy-analyst
https://www.rttnews.com/3231243/amgen-to-present-lumakras-combination-data-from-phase-1b-study-on-kras-g12c-mutated-cancers.aspx?refresh=1
https://www.evaluate.com/vantage/articles/news/snippets/mirati-moves-independent-future
https://www.fiercepharma.com/pharma/mirati-hot-its-tail-amgen-s-lumakras-combo-heads-into-late-stage-colorectal-cancer-testing
https://www.prnewswire.com/news-releases/lumakras-sotorasib-combined-with-vectibix-panitumumab-showed-encouraging-efficacy-and-safety-in-patients-with-kras-g12c-mutated-colorectal-cancer-301378188.html
https://www.biopharmadive.com/news/amgen-lumakras-colorectal-cancer-combination/606700/
https://www.biospace.com/article/releases/health-canada-approves-lumakras-sotorasib-the-first-and-only-targeted-treatment-for-patients-with-kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer/
https://www.pharmaceutical-technology.com/news/mhra-approves-amgen-sotorasib/
https://www.fiercepharma.com/pharma/amgen-s-high-profile-cancer-med-lumykras-set-for-rollout-england-thanks-to-nhs-access-deal
https://www.clinicaltrialsarena.com/news/amgen-trial-lumakras-nsclc/
http://www.pharmafile.com/news/587550/nhs-lung-cancer-patients-receive-amgen-s-tumour-stopping-drug
https://www.prnewswire.com/news-releases/amgen-presents-new-data-from-thoracic-oncology-portfolio-at-wclc21-301371754.html
https://endpts.com/weeks-after-dropping-big-response-data-amgen-lines-up-priority-review-for-kras-hopeful-sotorasib-in-nsclc/
https://www.prnewswire.com/news-releases/fda-grants-sotorasib-priority-review-designation-for-the-treatment-of-patients-with-kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer-301229256.html
https://investors.amgen.com/news-releases/news-release-details/amgen-announces-breakthrough-therapy-designation-granted
https://www.fiercebiotech.com/biotech/wclc-amgen-s-kras-drug-keeps-it-consistent-phase-2-as-global-filings-are-underway
https://www.clinicaltrialsarena.com/news/amgen-sotorasib-nsclc-trial/
https://www.prnewswire.com/news-releases/amgens-investigational-kras-g12c-inhibitor-sotorasib-demonstrated-rapid-deep-and-durable-responses-in-previously-treated-patients-with-advanced-non-small-cell-lung-cancer-301217636.html
Market Place
Share 
